Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester? (ADKETONE)
ADPKD
About this trial
This is an interventional treatment trial for ADPKD focused on measuring ketone ester
Eligibility Criteria
Inclusion Criteria: - ADPKD patients (diagnosis based on genetics or imaging) ≥ 16 and ≤ 70 years. Total Kidney Volume ≥ 600 mL. eGFR (CKD-EPI) ≥ 30 ml/min/1.73m2. Normal blood glucose, HbA1C and ketones. Women of childbearing potential who are non-lactating and using an effective form of birth control. Stable disease-modifying treatment for the last 2 months. Well controlled hypertension (stable antihypertensive medications for at least 2 months). BMI > 18 < 30. Written informed consent. Exclusion Criteria: Exposure to a ketogenic diet or intermittent fasting for more than 2 weeks within 6 months before inclusion. Significant weight-loss (> 10%) within 6 months before inclusion. Diabetes mellitus. Conditions prohibiting the use of a ketogenic diet (liver damage, pancreatic failure, pyruvate-carboxylase deficiency, defects in fatty acid oxidation/gluconeogenesis/ketolysis/neogenesis, hyperinsulinism), based on patient history. Diagnosis with any disorder of fatty acid metabolism based on patient history. Eating disorder. Alcohol abuse. Contraindication for MRI. Participation in other interventional trial.
Sites / Locations
Arms of the Study
Arm 1
Experimental
Ketone Ester
Up to 100g ketone ester daily for 56 days